RIGL [NASD]
Rigel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.48 Insider Own0.80% Shs Outstand172.84M Perf Week11.00%
Market Cap147.15M Forward P/E- EPS next Y-0.26 Insider Trans242.48% Shs Float170.76M Perf Month18.60%
Income-82.60M PEG- EPS next Q-0.13 Inst Own77.60% Short Float / Ratio3.23% / 2.05 Perf Quarter-41.71%
Sales89.40M P/S1.65 EPS this Y40.40% Inst Trans-8.74% Short Interest5.51M Perf Half Y-50.97%
Book/sh-0.11 P/B- EPS next Y49.00% ROA-59.00% Target Price3.58 Perf Year-68.07%
Cash/sh0.46 P/C1.80 EPS next 5Y- ROE- 52W Range0.64 - 3.52 Perf YTD-68.55%
Dividend- P/FCF- EPS past 5Y32.20% ROI-26.00% 52W High-76.29% Beta1.29
Dividend %- Quick Ratio2.20 Sales past 5Y48.90% Gross Margin97.90% 52W Low30.23% ATR0.07
Employees165 Current Ratio2.30 Sales Q/Q4.20% Oper. Margin-88.50% RSI (14)57.09 Volatility9.84% 8.25%
OptionableYes Debt/Eq- EPS Q/Q10.20% Profit Margin-92.40% Rel Volume22.15 Prev Close0.68
ShortableYes LT Debt/Eq- EarningsNov 03 AMC Payout- Avg Volume2.69M Price0.83
Recom2.70 SMA2013.21% SMA50-3.52% SMA200-50.53% Volume59,622,226 Change21.84%
Jun-09-22Downgrade Citigroup Buy → Neutral
Jun-08-22Downgrade Piper Sandler Overweight → Neutral $7 → $1
Jun-08-22Downgrade Cantor Fitzgerald Overweight → Neutral $6 → $1
Mar-23-22Initiated B. Riley Securities Neutral $4
Nov-09-20Downgrade JP Morgan Overweight → Neutral
Nov-15-19Resumed Cantor Fitzgerald Overweight $7 → $5
Sep-26-19Resumed JP Morgan Overweight $7
Mar-01-19Reiterated Cantor Fitzgerald Overweight $9 → $7
Aug-27-18Initiated Citigroup Buy $8.50
May-02-18Reiterated Cantor Fitzgerald Overweight $6 → $9
Show Previous Ratings
Dec-03-22 08:55AM
Dec-02-22 12:43PM
06:37AM
Dec-01-22 05:03PM
Nov-12-22 08:19AM
04:05PM Loading…
Nov-10-22 04:05PM
Nov-03-22 06:05PM
04:01PM
09:24AM
Nov-02-22 06:41AM
Nov-01-22 04:01PM
Oct-27-22 08:30AM
Oct-12-22 12:34PM
Oct-11-22 07:36AM
Oct-10-22 05:44PM
04:45PM Loading…
04:45PM
Sep-21-22 06:29AM
Sep-12-22 07:00AM
Sep-06-22 08:30AM
Aug-03-22 08:14AM
Aug-02-22 06:05PM
04:02PM
04:01PM
Jul-26-22 08:30AM
Jul-09-22 08:27AM
Jun-16-22 06:18AM
Jun-15-22 01:26PM
Jun-09-22 12:48PM
Jun-08-22 04:56PM
09:31AM
07:00AM Loading…
07:00AM
Jun-05-22 09:04AM
May-03-22 05:35PM
04:01PM
Apr-26-22 08:30AM
Apr-20-22 06:46AM
Apr-08-22 07:30AM
Mar-08-22 08:05AM
Mar-06-22 06:42AM
Mar-01-22 05:45PM
04:01PM
Feb-22-22 08:30AM
05:09AM
Feb-11-22 08:45AM
Jan-17-22 09:46AM
Jan-12-22 01:29PM
Jan-10-22 04:15PM
08:40AM
Jan-07-22 07:00PM
Dec-21-21 08:30AM
Dec-16-21 09:00AM
Dec-10-21 08:56AM
Nov-15-21 03:48PM
08:30AM
Nov-09-21 07:30AM
Nov-04-21 03:01PM
Nov-02-21 05:35PM
04:01PM
Oct-29-21 10:27AM
Oct-26-21 07:30AM
Oct-08-21 04:50PM
Sep-02-21 07:30AM
Sep-01-21 07:30AM
Aug-26-21 07:31AM
Aug-18-21 11:47AM
Aug-17-21 06:03PM
Aug-16-21 04:30PM
10:27AM
Aug-13-21 07:30AM
Aug-11-21 08:52AM
Aug-06-21 08:21AM
Aug-03-21 05:45PM
04:01PM
Jul-30-21 12:47PM
Jul-27-21 03:03PM
07:30AM
Jul-24-21 06:37AM
Jul-14-21 07:30AM
Jun-29-21 02:50PM
07:30AM
Jun-21-21 07:41AM
May-26-21 07:30AM
May-14-21 07:30AM
May-05-21 06:25PM
04:01PM
02:30PM
Apr-28-21 07:30AM
Apr-20-21 06:46AM
Apr-16-21 06:25PM
Apr-14-21 09:04AM
Apr-13-21 04:02PM
07:00AM
Apr-07-21 07:30AM
Mar-11-21 07:30AM
Mar-02-21 11:51PM
05:55PM
04:01PM
02:30PM
Feb-23-21 07:30AM
Feb-21-21 07:21AM
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RODRIGUEZ RAUL RCEO, PresidentJun 09Buy0.691,000,000688,4001,391,776Jun 13 04:36 PM